Aro Biotherapeutics to Present Data on Lead Program, ABX900, at AACR

– Avidity Effect of a Single – Chain Multispecific Centyrin Results in
Potent Inhibition of Tumors Expressing MET and EGFR Receptors

– Multispecific EGFR/MET Centyrin may have broad utility beyond NSCLC in
patient populations in which tumors are primarily driven by EGFR and MET

PHILADELPHIA–(BUSINESS WIRE)–Aro Biotherapeutics, a biotechnology company focused on the research and
development of Centyrins to transform the treatment of cancer and other
serious diseases, has announced the acceptance of its poster, entitled, “ABX9xx:
A bispecific centyrin that synergizes to attenuate intracellular
signaling in MET/EGFR positive tumors,” at the American Association
for Cancer Research’s 2019 Annual Meeting. The poster will be presented
on Wednesday, April 3, 2019 at the Georgia World Congress Center in
Exhibit Hall B.

“Aro has been in existence for just over a year, and so we are very
pleased to have quickly generated exciting new data that meets the AACR
standards for presentation in such a short period of time,” said Sue
Dillon, PhD, Co-founder and Chief Executive Officer of Aro. “Our
proprietary lead program, which we’re referring to as the ABX900 Series,
leverages many of the unique biophysical properties of Centyrins, which
are small, simple, ultra-stable and ultra-soluble proteins. With the
unique binding characteristics, biodistribution and efficient
manufacturing in E. coli, we believe that ABX900 will be well
differentiated vs bi-specific mAbs and small molecules that target the
EGFR and MET receptors. For example, we have shown that ABX900 achieves
potent anti-proliferative activity against a variety of tumors
expressing MET and EGFR mutations, amplified MET and WT receptors, many
of which are resistant to Tagrisso.”

Building a Pipeline of Life Changing Therapies

Centyrins are small, structurally simple, ultra-stable, highly soluble
proteins. These characteristics enable the discovery of medicines with
new mechanisms of action for cancer and other devastating diseases.
Aro’s lead program, which is a bi-specific Centyrin, is in late-stage
lead optimization for advanced non-small cell lung cancer. Aro’s second
therapeutic program is focused on creating a Centyrin-siRNA conjugate
for other forms of cancer. This first-of-its-kind combination is
designed to address unmet medical needs by targeting drug payloads in
high concentration to the site of disease, while lowering the toxicity
to non-target organs. The company holds an exclusive worldwide license
for research, development, manufacturing and commercialization of
Centyrin protein therapeutics.

About Aro Biotherapeutics

Aro is a biotechnology company focused on the research and development
of a new generation of protein biologics called Centyrins. The company
is developing a wholly-owned pipeline of Centyrins for oncology and
immunology, and is working with leaders in the industry on leveraging
Centyrins for delivery of a variety of drug payloads, including nucleic
acid drugs for a diverse set of diseases. For more information, visit www.arobiotx.com.

Contacts

Media Contact
Mike Beyer
Sam Brown Inc.
[email protected]
312-961-2502